Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15630DOI Listing

Publication Analysis

Top Keywords

reversal protein-losing
4
protein-losing enteropathy
4
enteropathy surgical
4
surgical revision
4
revision jejunal
4
jejunal roux-en-y
4
roux-en-y loop
4
loop liver
4
liver transplantation
4
transplantation lymphangiectasia!
4

Similar Publications

Background: A subgroup of CHDs can only be treated palliatively through a Fontan circulation. In case of a failing Fontan situation, serum proteins are lost unspecifically and can also lead to a loss of vaccine antibodies. In a failing Fontan situation, heart transplantation may be the only feasible option.

View Article and Find Full Text PDF

An evaluation of pozelimab for the treatment of CHAPLE disease.

Expert Opin Biol Ther

January 2025

Division of Allergy and Immunology, Department of Pediatrics, School of Medicine, Marmara University, Istanbul, Turkey.

Introduction: CHAPLE disease is a severe, ultra-rare disorder caused by CD55 gene mutations, leading to uncontrolled complement hyperactivation, protein-losing enteropathy, and systemic thrombosis. Recent advances in targeted therapies, particularly the C5 inhibitor pozelimab (Veopoz), offer new treatment options by addressing complement dysregulation, marking a shift from symptomatic to precision therapy.

Areas Covered: This review explores the pathophysiology, clinical manifestations, and current treatments for CHAPLE disease.

View Article and Find Full Text PDF

Overview of secondary immunodeficiency.

Allergy Asthma Proc

September 2024

From the Division of Pediatric Allergy and Immunology, Department of Pediatrics, University of Rochester Medical Center, Rochester, New York; and.

In contrast to inborn errors of immunity (IEI), which are inherited disorders of the immune system that predispose to infections, malignancy, atopy, and immune dysregulation, secondary immunodeficiencies and immune dysregulation states (SID) are acquired impairments in immune cell function and/or regulation, and may be transient, reversible, or permanent. SIDs can derive from a variety of medical comorbidities, including protein-losing conditions, malnutrition, malignancy, certain genetic syndromes, prematurity, and chronic infections. Medications, including immunosuppressive and chemotherapeutic drugs, can have profound effects on immunity and biologic agents used in rheumatology, neurology, and hematology/oncology practice are increasingly common causes of SID.

View Article and Find Full Text PDF
Article Synopsis
  • Constrictive pericarditis can lead to protein-losing enteropathy (PLE) through a mechanism involving intestinal lymphangiectasia, although this is a rare occurrence.
  • A comprehensive review of the literature was conducted using specific medical terms to explore the clinical management of PLE related to constrictive pericarditis.
  • Diagnosing constrictive pericarditis typically involves cardiac catheterization, with imaging techniques like MRI, CT scans, and endoscopic methods aiding in the identification of lymphangiectasias; treatment such as pericardiectomy may help reverse PLE symptoms.
View Article and Find Full Text PDF

Chronic giardia infection can lead to non-erosive gastrointestinal disorders, including protein-losing enteropathy (PLE). This report describes non-diarrheal PLE in chronic giardiasis in children with defective humoral immunity. Methods: The retrospective report is related to 2 children known to have a monogenic inborn error of immunity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!